Strides Arcolab’s arm has entered into a build and lease agreement with Bio-XCell for the construction of 1,40,000 sq feet facility at Johor, Malaysia
Stelis Biopharma, a wholly-owned arm of Strides Arcolab, has commenced construction of its Rs 370 crore ($60 million) biologics facility at Malaysia.
Stelis has entered into a build and lease agreement with Bio-XCell for the construction of 1,40,000 sq feet facility at Johor, Malaysia which is expected to be completed in next 24 months, Strides Arcolab said in a statement.
According to a PTI report, the facility will incorporate next—gen single use bio-processing technology with both mammalian and microbial manufacturing suites, it added.
Joe Thomas, Chief Executive Officer, Stelis Biopharma said, “With its strong commitment to bio-economy, attractive incentives, quality infrastructure and enabling ecosystem, we are confident of making this our bio-manufacturing hub for regional and global markets.”
The facility will employ 180 people in R&D and manufacturing.
EP News Bureau – Mumbai